Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression

Documenti analoghi

• Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
  di: Giovanni Antonio Silverii, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
  di: Richard J. MacIsaac, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
  di: Andrea Saglietto, et al.
  Pubblicazione: (2024)
• Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
  di: Natalia Andrea Rojas-Henao
  Pubblicazione: (2018)
• Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
  di: Yu Mi Kang, et al.
  Pubblicazione: (2025)